Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

被引：0

作者：

Huang, Si-Man ^{[1
,2
,3
]}

Wan, Chao-Ling ^{[1
,2
,3
]}

Cao, Han-Yu ^{[1
,2
,3
]}

Li, Yan-Yan ^{[1
,2
,3
]}

Qian, Chong-Sheng ^{[1
,2
,3
]}

Zhou, Hai-Xia ^{[1
,2
,3
]}

Xu, Ming-Zhu ^{[1
,2
,3
]}

Hu, Xiao-Hui ^{[1
,2
,3
]}

Dai, Lan ^{[1
,2
,3
]}

Dai, Hai-Ping ^{[1
,2
,3
]}

Xue, Sheng-Li ^{[1
,2
,3
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, 188 Shizi St, Suzhou 215006, Peoples R China

[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

[3] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

来源：

CLINICAL CASE REPORTS | 2023年 / 11卷 / 12期

关键词：

B-ALL; CD22; inotuzumab ozogamicin; MRD positive; relapsed and refractory; ADULTS;

D O I：

10.1002/ccr3.8289

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

引用

页数：5